Previous close | 86.10 |
Open | 86.08 |
Bid | 86.80 x 800 |
Ask | 88.28 x 800 |
Day's range | 85.58 - 86.69 |
52-week range | 74.09 - 94.26 |
Volume | |
Avg. volume | 2,057,647 |
Market cap | 181.968B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 27.08 |
EPS (TTM) | 3.17 |
Earnings date | N/A |
Forward dividend & yield | 3.33 (3.77%) |
Ex-dividend date | 08 Mar 2022 |
1y target est | 104.25 |
Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.20 on 13th of...
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a
Novartis ( VTX:NOVN ) Full Year 2022 Results Key Financial Results Revenue: US$51.8b (down 2.0% from FY 2021). Net...